HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.

Abstract
Phosphate binders are useful for the treatment of hyperphosphatemia in hemodialysis (HD) patients. This study was performed to examine the effects of switching from calcium carbonate (CC) to lanthanum carbonate (LC) on bone mineral metabolism and inflammatory markers in HD patients. We conducted 29 stable HD patients receiving CC, which was replaced by LC and followed-up for 12 weeks. Patients underwent determinants of blood chemistries such as serum calcium (Ca), phosphorus, parathyroid hormone (PTH) and vitamin D status, and interleukin-6 (IL-6) mRNA levels in whole blood cells were evaluated by real-time PCR just before and after the treatment with LC. Corrected Ca [corrected] levels were significantly reduced, but serum phosphorus levels (P levels) were unchanged after LC treatment. Switching to LC increased whole-PTH, osteocalcin, 1,25(OH)(2) D(3) levels and 1,25(OH)(2) D(3)/25(OH)D(3) ratio. 1,25(OH)(2) D(3)/25(OH)D(3) ratio was negatively correlated with HD duration. Furthermore, whole blood cell IL-6 mRNA levels were significantly reduced by LC treatment. We provided that the switching from CC to LC improved Ca overload and ameliorated vitamin D and inflammatory status in HD patients. These observations suggest that LC may play a protective role for the progression of atherosclerosis and vascular calcification in these patients.
AuthorsRie Manabe, Kei Fukami, Ryotaro Ando, Kazuko Sakai, Takuo Kusumoto, Takuma Hazama, Takeki Adachi, Yusuke Kaida, Yosuke Nakayama, Seiji Ueda, Keisuke Kohno, Yoshifumi Wada, Sho-ichi Yamagishi, Seiya Okuda
JournalTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 17 Suppl 1 Pg. 35-40 (Apr 2013) ISSN: 1744-9987 [Electronic] Australia
PMID23586511 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© 2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis.
Chemical References
  • Interleukin-6
  • Parathyroid Hormone
  • RNA, Messenger
  • Vitamin D
  • Phosphorus
  • lanthanum carbonate
  • Lanthanum
  • Calcium Carbonate
  • Calcium
Topics
  • Aged
  • Bone and Bones (drug effects, metabolism)
  • Calcium (blood)
  • Calcium Carbonate (administration & dosage, therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammation (drug therapy, etiology)
  • Interleukin-6 (metabolism)
  • Lanthanum (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Parathyroid Hormone (blood)
  • Phosphorus (blood)
  • Prospective Studies
  • RNA, Messenger (metabolism)
  • Real-Time Polymerase Chain Reaction
  • Renal Dialysis (methods)
  • Vitamin D (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: